Ms. Susan Pietropaolo reports

APTOSE ENTERS INTO $25 MILLION COMMITTED EQUITY FACILITY

Aptose Biosciences Inc. has entered into a common share purchase agreement and registration rights agreement with an institutional investor.

The agreement governs a committed equity facility that provides Aptose the right, in its sole option and discretion without obligation, to sell and issue up to $25-million of its common shares over the course of 24 months to the investor, subject to certain conditions being met, and subject to certain limitations and conditions imposed by Nasdaq, the Securities and Exchange Commission, and other regulators.

No common shares will be sold on the Toronto Stock Exchange (TSX) or other trading market in Canada under the common share purchase agreement. The TSX has conditionally approved the committed equity facility. For the purposes of TSX approval, the company relied on the exemption set forth in Section 602.1 of the TSX company manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq, provided that the transaction is being completed in compliance with the requirements of such recognized exchange.

About Aptose Biosciences Inc.

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small-molecule cancer therapeutics pipeline includes products designed to provide single-agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the Aptivate international phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

We seek Safe Harbor.